In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • MicroRNA-29a-5p Protects Against Cerebral Ischemia and Reperfusion Injury After Endovascular Thrombectomy in Acute Stroke

    Final Number:
    559

    Authors:
    Zhongsong Shi; Yonghua Tuo; Zhong Liu; Lei Feng

    Study Design:
    Laboratory Investigation

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2017 Annual Meeting

    Introduction: Cerebral ischemia and reperfusion (I/R) injury occurs after endovascular mechanical thrombectomy for patients with acute ischemic stroke. MicroRNA-29a (miR-29a) is involved in regulating cerebral ischemia process, but its underlying mechanism is unclear. This study investigated the role of miR-29a in cerebral I/R injury after mechanical reperfusion in transient middle cerebral artery occlusion (tMCAO) animal model.

    Methods: The intraluminal filament tMCAO model was established in male rats with 2 hour ischemia followed by reperfusion. The expression of miR-29a in the infarction core and peri-infarct cortex and whole blood were quantified at 0, 3, 12, and 24 hour after reperfusion. Permanent MCAO model was also evaluated at 2-hour and 24-hour ischemia. Intravenous miR-29a-5p agomir was delivered immediately after reperfusion or before reperfusion. Infarct volume, brain water content, neurological score and blood-brain barrier damage, and the expression of miR-29a-5p, NADPH oxidase (NOX4), aquaporin-4 and caspase-3 were determined at 24-hour after ischemia.

    Results: MiR-29a-5p levels in the infarction core and peri-infarct cortex were significantly decreased at 3 hours after reperfusion in tMCAO group. The decreased levels of miR-29a-5p in brain tissue and whole blood lasted for 24 hours after ischemia. Intravenous miR-29a-5p agomir reduced infarct volume (p<0.01) at 24-hour after ischemia compared to the tMCAO group. MiR-29a-5p agomir attenuated brain edema and reduced reperfusion-induced blood-brain barrier breakdown, resulting in improved neurological outcome (p<0.05). Intravenous miR-29a-5p agomir increased the expression of miR-29a-5p and suppressed the up-regulation of NOX4, AQP4, caspase-3 in both the infarction core and peri-infarct cortex compared with the tMCAO group (p<0.05). Dual-luciferase reporter system showed that NOX4 was the direct target gene of miR-29a-5p.

    Conclusions: MiR-29a-5p overexpression protects against cerebral I/R injury via downregulating NOX 4. Infusion of miR-29a-5p agomir immediately after reperfusion and before reperfusion represents a novel adjunctive therapeutic strategy to improve outcome after mechanical reperfusion for acute stroke.

    Patient Care: Our translational research suggest that intravenous infusion of miR-29a-5p agomir immediately after reperfusion and before reperfusion may represent a novel adjunctive therapeutic strategy to improve outcome after endovascular mechanical reperfusion for acute ischemic stroke.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) Describe the role of miR-29a-5p in cerebral ischemia and reperfusion injury after mechanical reperfusion in transient middle cerebral artery occlusion animal model. 2) Discuss the mechanism of miR-29a-5p as a potential neuroprotective target. 3) Identify an effective treatment by intravenous infusion of miR-29a-5p agomir immediately after reperfusion and before reperfusion to improve outcome after mechanical reperfusion for acute stroke in rat models.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy